Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement

•Available prospective evidence is mixed for whether SCR improves overall survival.•Reviewing similarities & differences of clinical trials is key to applying findings to practice.•GOG-0213, DESKTOP III, and SOC-1 enrolled highly selected cohorts of patients.•Patient selection is critical when c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 2021-12, Vol.163 (3), p.448-452
Hauptverfasser:	Harrison, R., Zighelboim, I., Cloven, N.G., Marcus, J.Z., Coleman, R.L., Karam, A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoma, Ovarian Epithelial - drug therapy Carcinoma, Ovarian Epithelial - surgery Clinical Trials, Phase III as Topic Cytoreduction Cytoreduction Surgical Procedures - methods Female Humans Multicenter Studies as Topic Neoplasm Recurrence, Local - surgery Ovarian cancer Ovarian Neoplasms - surgery Platinum-sensitive Practice Guidelines as Topic Randomized Controlled Trials as Topic Secondary cytoreduction Surgery
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•Available prospective evidence is mixed for whether SCR improves overall survival.•Reviewing similarities & differences of clinical trials is key to applying findings to practice.•GOG-0213, DESKTOP III, and SOC-1 enrolled highly selected cohorts of patients.•Patient selection is critical when considering SCR as part of treatment for recurrent disease.•The goal of SCR should be complete resection of all visible disease.
ISSN:	0090-8258 1095-6859
DOI:	10.1016/j.ygyno.2021.10.008